NASDAQ · ICAD
iCAD, Inc.
$3.87+$0.14 (+3.75%)
iCAD, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
Loading market information…
AMEX · ASXC · USD
Stock price, earnings
Quote as of Aug 21, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Asensus Surgical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Asensus Surgical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Asensus Surgical, Inc., a medical technology enterprise established in 2006 and headquartered in Durham, North Carolina, focuses on the research, development, and commercialization of robotic medical devices. Its core mission is to elevate minimally invasive surgical procedures throughout the United States, Europe, and Asia through innovative robotic solutions. The company's unique approach involves digitally bridging the gap between surgeons and patients, thereby introducing a new paradigm of "Performance-Guided surgery." This system aims to equip surgeons with critical clinical intelligence, ensuring consistently superior patient outcomes and setting a higher benchmark for surgical standards. Key products include the Senhance Surgical system, a multi-port robotic platform that can maneuver up to four arms to precisely control surgical instruments and a camera during laparoscopic operations. Their product line also features a range of specialized instruments, such as 3mm diameter instruments, 3mm and 5mm hooks, and articulating tools. Additionally, they offer the Senhance ultrasonic system, an advanced energy device designed for accurate, controlled tissue ligation and division. The company, initially known as TransEnterix, Inc., officially rebranded to Asensus Surgical, Inc. in February 2021.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:30 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 | Mar 2, 2023 | -$0.070.0% vs estimate | $2.46M-29.48% vs estimate |
|---|
| Q3 2022 | Nov 10, 2022 | -$0.070.0% vs estimate | $2.56M-12.21% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.87+$0.14 (+3.75%)
iCAD, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
$1.88$0.00 (0.0%)
Jounce Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.99% below the high.
$3.01-$0.17 (-5.35%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.63% below the high.
$0.10-$0.00 (-0.21%)
Zomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
$2.05-$0.05 (-2.38%)
Aadi Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.22% below the high.
$3.39+$0.02 (+0.59%)
Miromatrix Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.07% below the high.
$1.20-$0.08 (-5.88%)
Berkeley Lights, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.78% below the high.
$30.03$0.00 (0.0%)
Neovasc Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.13% below the high.
